EuroPCR 2023

17 May 2023

LAA closure TAVI

Cutting-edge technologies: clinical updates on TES, BRS, TAVR and LAA closure

Sponsored by MicroPort

Anchorperson: A. Baumbach

Spokesperson: M. Leon

SHOW MORE

Summary

Watch this session to find out more about the three-year outcomes of the FUTURE-II Trial, the TARGET clinical trial roadmap, the TARGET IV NA Trial update, the twelve-month outcomes of the SAVE PROTECT Trial, and the quantitative aortographic assessment of regurgitation in patients treated with VitaFlow.

Learning Objectives

To understand the performance of new generation BRS after three-year follow-up
To get to know ongoing clinical studies on Firehawk TES
To understand the performance of VitaFlow compared to other self-expanding valves
To discover the new LAA closure device on the market and its performance after twelve months

Dr. Martin B. Leon

Speaker

Target clinical trials roadmap and TARGET IV NA trial update

Download presentation

Speaker

MicroPort LAAC Pivotal study - SAFE PROTECT randomised controlled trial one-year result

Download presentation

Speaker

Aortographic regurgitation assessment of TAVI patients treated with VitaFlow TAVI solution

Download presentation